TICAR
LOE ApproachingNDAINJECTIONINJECTABLE
Approved
Nov 1976
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
20
Data completeness
2/8 — Basic
Drug data last refreshed 9h ago · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
TICAR is a small-molecule injectable antibiotic approved in 1976 by GSK. The specific indication and mechanism of action are not publicly detailed in available data, but the product remains an active pharmaceutical with injectable delivery. TICAR represents a legacy product in GSK's portfolio with established clinical use.
LOE Approaching
With LOE approaching and moderate competitive pressure (30/100), commercial teams are likely planning transition strategies and managed care negotiations rather than growth initiatives.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (20)
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity, Pharmacodynamics and Clinical Activity of BBT001 Following Intravenous Administration in Participants With Chronic Spontaneous Urticaria (CSU)
Started Jun 2026
48 enrolled
Chronic Spontaneous Urticaria
A Study of MG-K10 in Chronic Spontaneous Urticaria
Started Apr 2026
226 enrolled
Chronic Spontaneous Urticaria (CSU)
A Study to Describe the Real-world Effectiveness, Safety and Patterns of Use of Dupilumab in Patients With Chronic Spontaneous Urticaria
Started Mar 2026
1 enrolled
Chronic Spontaneous Urticaria
A Real-World Study of Omalizumab Treatment Patterns in Chronic Urticaria Patients in China
Started Mar 2026
3,485 enrolled
Chronic Urticaria
Study of the Efficacy and Safety of ICP-332 in Participants With Chronic Spontaneous Urticaria
Started Feb 2026
344 enrolled
Chronic Spontaneous Urticaria (CSU)
Worked on TICAR at GSK? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.